A detailed history of Nuveen Asset Management, LLC transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 142,694 shares of SAGE stock, worth $1.52 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
142,694
Previous 142,694 -0.0%
Holding current value
$1.52 Million
Previous $3.09 Million 13.52%
% of portfolio
0.0%
Previous 0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$17.1 - $22.26 $22,554 - $29,360
1,319 Added 0.93%
142,694 $3.09 Million
Q3 2023

Nov 14, 2023

SELL
$16.75 - $48.98 $2.88 Million - $8.43 Million
-172,074 Reduced 54.9%
141,375 $2.91 Million
Q2 2023

Aug 14, 2023

BUY
$40.65 - $59.54 $7.06 Million - $10.3 Million
173,664 Added 124.24%
313,449 $14.7 Million
Q1 2023

May 15, 2023

SELL
$37.27 - $46.57 $661,766 - $826,896
-17,756 Reduced 11.27%
139,785 $5.87 Million
Q4 2022

Feb 14, 2023

SELL
$32.2 - $43.61 $821,164 - $1.11 Million
-25,502 Reduced 13.93%
157,541 $6.01 Million
Q3 2022

Nov 14, 2022

SELL
$32.28 - $43.27 $124,245 - $166,546
-3,849 Reduced 2.06%
183,043 $7.17 Million
Q2 2022

Aug 15, 2022

SELL
$27.52 - $37.99 $1.09 Million - $1.51 Million
-39,711 Reduced 17.52%
186,892 $6.04 Million
Q1 2022

May 16, 2022

SELL
$30.71 - $45.71 $645,247 - $960,412
-21,011 Reduced 8.49%
226,603 $7.61 Million
Q4 2021

Feb 14, 2022

BUY
$37.06 - $47.11 $465,584 - $591,842
12,563 Added 5.34%
247,614 $10.5 Million
Q3 2021

Nov 12, 2021

BUY
$40.26 - $57.37 $346,517 - $493,783
8,607 Added 3.8%
235,051 $10.4 Million
Q2 2021

Aug 16, 2021

BUY
$54.88 - $79.29 $2.58 Million - $3.72 Million
46,976 Added 26.18%
226,444 $12.9 Million
Q1 2021

May 17, 2021

SELL
$70.65 - $96.76 $3.03 Million - $4.14 Million
-42,832 Reduced 19.27%
179,468 $13.4 Million
Q4 2020

May 17, 2021

BUY
$58.41 - $89.06 $1.99 Million - $3.04 Million
34,104 Added 18.12%
222,300 $19.2 Million
Q4 2020

Feb 16, 2021

SELL
$58.41 - $89.06 $3.83 Million - $5.84 Million
-65,555 Reduced 25.83%
188,196 $16.3 Million
Q3 2020

Nov 16, 2020

SELL
$41.13 - $62.45 $1.1 Million - $1.67 Million
-26,684 Reduced 9.52%
253,751 $15.5 Million
Q2 2020

Aug 14, 2020

SELL
$25.95 - $43.15 $2.04 Million - $3.39 Million
-78,568 Reduced 21.89%
280,435 $11.7 Million
Q1 2020

May 14, 2020

SELL
$26.15 - $77.24 $4.46 Million - $13.2 Million
-170,727 Reduced 32.23%
359,003 $10.3 Million
Q4 2019

Feb 14, 2020

BUY
$60.18 - $154.77 $3.46 Million - $8.9 Million
57,482 Added 12.17%
529,730 $38.2 Million
Q3 2019

Nov 14, 2019

SELL
$140.29 - $189.96 $20.9 Million - $28.3 Million
-149,177 Reduced 24.01%
472,248 $66.3 Million
Q2 2019

Aug 15, 2019

BUY
$157.85 - $183.09 $98.1 Million - $114 Million
621,425 New
621,425 $114 Million
Q3 2018

Nov 13, 2018

SELL
$138.11 - $169.04 $747,313 - $914,675
-5,411 Closed
0 $0
Q2 2018

Aug 14, 2018

SELL
$140.36 - $175.76 $750,504 - $939,788
-5,347 Reduced 49.7%
5,411 $847,000
Q1 2018

May 14, 2018

BUY
$152.15 - $192.33 $295,779 - $373,889
1,944 Added 22.06%
10,758 $1.73 Million
Q4 2017

Feb 14, 2018

SELL
$60.72 - $167.34 $34,671 - $95,551
-571 Reduced 6.08%
8,814 $0
Q3 2017

Nov 14, 2017

BUY
$61.4 - $88.52 $576,239 - $830,760
9,385
9,385 $585,000

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $631M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.